Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia

Wioleta M. Zelek, Ryan J. Bevan, Bryan Paul Morgan

UK Dementia Research Institute Cardiff and Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales CF14 4XN, United Kingdom

1. Introduction

The complement system is an important driver of inflammation in diverse settings, contributing to immune defence but, when dysregulated, causing tissue damage and pathology. In neurodegenerative diseases (NDDs), complement has been implicated both as a mediator of disease but their relative contributions remain unclarified. Here we have focussed on the MAC, a lytic and pro-inflammatory effector, in the AppNL-G-F mouse amyloidopathy model. To test the role of MAC, we back-crossed to generate AppNL-G-F mice deficient in C7, an essential MAC component. C7 deficiency ablated MAC formation, reduced synapse loss and amyloid load and improved cognition compared to complement-sufficient AppNL-G-F mice at 8–10 months age. Adding back C7 caused increased MAC formation in brain and an acute loss of synapses in C7-deficient AppNL-G-F mice. To explore whether C7 was a viable therapeutic target, a C7-blocking monoclonal antibody was administered systemically for one month in AppNL-G-F mice aged 8–9 months. Treatment reduced brain MAC and amyloid deposition, increased synapse density and improved cognitive performance compared to isotype control-treated AppNL-G-F mice. The findings implicate MAC as a driver of pathology and highlight the potential for complement inhibition at the level of MAC as a therapy in Alzheimer’s disease.

* Corresponding authors at: Cardiff University, Cardiff, Wales CF14 4XN, Wales, UK.
E-mail addresses: zeleksw@cardiff.ac.uk (W.M. Zelek), morganbp@cardiff.ac.uk (B.P. Morgan).

https://doi.org/10.1016/j.bbi.2024.03.017
Received 5 December 2023; Received in revised form 28 February 2024; Accepted 11 March 2024
Available online 12 March 2024
0889-1591/Crown Copyright © 2024 Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
App<sup>NL–G–F</sup> mice were treated for 4 weeks with a mouse C7-blocking monoclonal antibody (mAb) previously shown to completely block systemic complement activity in wild-type mice (Zelek & Morgan, 2020). Impact on brain complement dysregulation, disease and cognition was assessed at end point in comparison with a control mAb.

2. Materials and methods

2.1. Reagents and sera

All chemicals, except where otherwise stated, were obtained from Fisher Scientific UK (Loughborough, UK) or Sigma Aldrich (Gillingham, UK) and were of analytical grade. All tissue culture reagents and plastics were from Invitrogen Life Technologies (Paisley, UK). Sheep erythrocytes in Alsever’s solution were from TCS Biosciences (Claydon, UK). Human and animal sera were prepared in house from freshly collected blood. For human serum, blood was clotted at room temperature (RT) for 1 h (h), then placed on ice overnight for clot retraction before centrifugation and harvesting of serum. For mouse serum, blood was placed on ice 5 min after harvest and clotted for 2 h on ice before serum harvest. Sera were stored in aliquots at −80 °C and not subjected to freeze–thaw cycles.

2.2. Animals

Mice were housed in groups in open-topped cages with 12-hour light/dark cycles and unlimited access to food and water. To produce homozygous C7-deficient mice, heterozygous C7 deficient mice (C57BL/6NJ-C7em1(IMPC)/J/Mmjax C7<sup>+</sup>−; Jackson Immunoresearch, Baltimore, USA) were interbred in-house (Zelek & Morgan, 2020; Carpanini et al., 2022). App<sup>NL–G–F</sup> knock-in mice expressing human APP with the Swedish (KM670/671NL), Iberian (I716F), and Arctic (E693G) mutations were generously provided by Dr. Takaomi Saido (Saito et al., 2020; Morgan, 2000). All mice were housed in groups in open-topped cages with 12-hour light/dark cycles and unlimited access to food and water. To produce homozygous C7-deficient mice, heterozygous C7 deficient mice (C57BL/6NJ-C7em1(IMPC)/J/Mmjax C7<sup>+</sup>−; Jackson Immunoresearch, Baltimore, USA) were interbred in-house (Zelek & Morgan, 2020; Carpanini et al., 2022). App<sup>NL–G–F</sup> knock-in mice expressing human APP with the Swedish (KM670/671NL), Iberian (I716F), and Arctic (E693G) mutations were generously provided by Dr. Takaomi Saido (Saito et al., 2014). Both males and females were used. Within each experiment, a single sex was used because the well-described differences in complement activity between male and female mice add a confounder to mixed-sex studies (Kotimaa et al., 2016). The UK Home Office Animals Scientific Procedures Act of 1986 and regional institutional policies were followed throughout every animal procedure. Mice were humanely sacrificed at the stated intervals using CO<sub>2</sub> asphyxia, then immediately perfused intracardially with phosphate buffered saline (PBS). Brains were removed, cut sagitally, one half fixed in 1.5 % (w/v) paraformaldehyde (PFA) for immunocytochemistry and DiOlistic spine labelling, and the other half snap frozen for ELISA experiments.

2.3. Testing the role of C7 in neurodegeneration in App<sup>NL–G–F</sup> mouse

To test whether C7, and by inference the MAC, contributed to neurodegeneration in App<sup>NL–G–F</sup> mice, we first back-crossed onto C7 deficient. Unmodified App<sup>NL–G–F</sup> female mice were compared to co-housed C7-deficient (App<sup>NL–G–F</sup>/C7<sup>−/−</sup>) female mice at 8–9 months (7 mice per group). Single-gender groups were used in this and all other studies because of the known effects of gender on complement activity in mice (Kotimaa et al., 2016). Tests of cognition were performed as detailed below, brains harvested and complement activation, cytokine levels, amyloid load and synapse density measured as detailed in the sections below.

To confirm that the impact on the measured parameters was a direct effect of C7 deficiency, a C7 addback experiment was performed. App<sup>NL–G–F/C7<sup>−/−</sup>−</sup> males (8–10 months, 10 per group) were given either human C7 (in house affinity purified as described previously; Zelek & Morgan, 2020; Morgan, 2000) or PBS control, respectively, for a week. Human C7 was administered in three IP doses (16 mg/kg; 8 mg/kg; 8 mg/kg) at two-day intervals over a week. This dosing schedule was chosen from preliminary experiments that demonstrated near-physiological plasma C7 levels and complete block of haemolytic activity; the impact on complement activity was confirmed by measuring serum haemolytic activity prior to and during treatment using the CH50 assay described below.

To test whether systemically delivered anti-C7 blocking mAb influenced neurodegeneration, 8–9 month female App<sup>NL–G–F</sup> were treated for one month with either the C7-blocking mAb 73D1 (n = 5) or D1.3 control IgG antibody (n = 5) delivered IP with an initial loading dose of 40 mg/kg followed by 20 mg/kg twice weekly. Impact on complement activity was confirmed by measuring haemolytic activity in blood samples taken prior to and during treatment using the CH50 assay described below.

2.4. CH50 haemolysis assay

Systemic complement activity in the mice was assessed using a classical pathway (CP) haemolysis assay (CH50) as previously described (Zelek & Morgan, 2020; Zelek et al., 2019b). For assessment of C7 activity, a modified assay was developed (Zelek, 2021); the human and mouse terminal pathway components are highly compatible which allows use small amounts of mouse serum in the assay (Zelek & Morgan, 2020; Zelek, 2021). Antibody-sensitised sheep erythrocytes (SHEA; Amboceptor, Siemens, #ORLC25, Cruinn Diagnostics, Dublin, UK), at 2 % in HEPES-buffered saline containing Ca<sup>2+</sup> and Mg<sup>2+</sup> (HBS-Ca-Mg) were incubated with C7-depleted human serum (NH-S7; 5 % in HBS-Ca-Mg) plus serial dilutions of normal mouse serum (NMS; 2.5 – 0 %) or the test mouse serum in duplicate in 96-well round-bottomed plates, incubated at 37 °C for 30 min, centrifuged and haemoglobin in the supernatant measured by absorbance at 405 nm. Percent haemolysis was calculated for each sample from the formula: % Lysis = Absorbance (Abs) sample - Abs background)/(|Abs max - Abs background) x 100 %.

2.5. Preparation of mouse brain homogenates

Total brain homogenates (TBH) were prepared by homogenising the snap-frozen brain hemispheres for 5 min on ice in 0.3 ml of ice-cold Neuronal Protein Extraction Reagent (N-PER<sup>TM</sup>, 87792, ThermoFisher Scientific, Loughborough, UK) containing 1x EDTA-free protease inhibitor (4693159001, Roche cOmplete mini EDTA-free, Sigma Aldrich). Homogenates were centrifuged at 13 000 rpm for 20 min at 4 °C, and supernatant (TBH) collected. The remaining pellet was further processed as previously described (Kaplan et al., 2003) to prepare the brain tissue bound protein (TCP) extracts that contain aggregated Aβ. In brief, pellets were resuspended in 0.3 ml of 8 M Guanidine-HCl (24115, Thermofisher), homogenised on ice as described above, incubated on ice for 30 min, centrifuged as above, and the resulting supernatant (TBP) collected. Total protein concentration in TBH and TBP extracts was measured (Pierce Micro BCA Kit: 23235, ThermoFisher) and concentrations adjusted by dilution to 40–70 mg/ml prior to aliquoting, snap freezing and storage at −80 °C until testing. Samples were not subjected to freeze–thaw cycles. Levels of all analytes measured in the ELISA described below were expressed relative to total protein measured using the BCA assay.

2.6. Detection of complement activation products in mouse brain homogenates

For detection of the terminal complex (TCC), a marker of terminal pathway activation and MAC formation, Maxisorp (ThermoFisher) 96-well plates were coated with rabbit anti-rat/mouse C9 (in-house; 10 µg/ml in bicarbonate buffer pH 9.6) and incubated at RT overnight (O/N). The wells were then blocked (30 min at 37 °C) with 3 % BSA in PBS 0.05 % Tween 20 (PBS-T) and rinsed in PBS-T. TBP were diluted to 0.5 mg/ml in PBS-T-EDTA (0.3 % BSA PBS with 10 mM EDTA), 50 µl aliquots added in duplicate to the ELISA wells and incubated O/N at 4 °C. Standard curves were generated using activated mouse serum, batch-generated by incubation with Zymosan A (7 mg/ml; Pierce, #21327).
and aggregated human IgG (50 µg/ml; in house) for 32 h at 37 °C in a shaking water bath, activating both classical and alternative pathways to completion. The reaction was stopped by centrifugation at 4600 rpm for 15 min at 4 °C and the supernatant (activated mouse serum; Act-NMS) collected and stored at −80 °C in aliquots. For standard curves, Act-NMS was double-diluted in PBS-T-EDTA from a starting dilution of 1:3 in duplicates. Wells were washed with PBS-T then incubated (1.5 hr, RT) with HRP-labelled detection antibody mAb 12C3 anti-mouse TCC-neoantigen mAb (in house; 5 µg/ml in PBS-T-EDTA). After washing plates were developed with OPD, and the absorbance (492 nm) was recorded.

To measure mouse C3b/iC3b/C3c, plates were coated with 2/11 mAb anti-mouse C3b/iC3b/C3c (5 µg/ml, HM1065, Hycult Biotech, Uden, Netherlands) and incubated O/N at RT. After blocking in 3 % BSA-PBS-T, plates were washed in PBS-T and TBP samples (1 in 800) were added, incubated O/N at 4 °C. The standard curve was generated using Act-NMS double-diluted in PBS-T-EDTA from a starting dilution of 1:1000 in duplicates. Plates were washed, and bound C3 fragments detected using in-house HRP-labelled rabbit anti-human C3 (cross-reactive with mouse C3), 1:500 in 0.3 % BSA-PBST-EDTA for 1.5 hr at RT. Plates were washed twice, developed using OPD and absorbance quantified as above.

To determine the intra- and inter-assay precision (%CV; <10 %), two NMS samples (1 in 40 for TTC, and 1 in 20,000 for C3 fragments ELISA) were used as an inter-assay control across all plates and assays.

2.7. Detection of IL-1β by ELISA in mouse brain

IL-1β levels in TBP were measured using a commercial ELISA kit (DY401-05, R&D Systems) in accordance with the manufacturer’s instructions. Briefly, wells were coated with capture antibody (1 in 250 in PBS, 100 µl/well) O/N at RT, washed, blocked, then incubated with 100 µl of TBH (1 in 2) or standards (serial dilutions: 0–1000 pg/ml). After washing, detection antibody was added and incubated, followed by streptavidin-HRP. Colour was developed with TMB, absorbance (450 nm) measured and IL-1β levels in the TBP samples read from the standard curve.

2.8. Detection of amyloid by ELISA in AppNL−G−F mouse brain

Human Aβ42 was measured in TBP extracts from AppNL−G−F mice (expressing human APP) using a commercial ELISA (ThermoFisher, KHB3442) in accordance with the manufacturer’s instructions. In short, TBP samples (1 in 8000) or standard (0–2000 pg/ml) were incubated in wells coated with capture antibody, wells washed, incubated with biotinylated detection antibody followed by streptavidin-HRP. Colour was developed with TMB, absorbance (450 nm) measured and Aβ42 levels in the TBP samples read from the standard curve.

2.9. DiOListic spine labelling, imaging, and analyses

Fixed brains were cut into 60 µm thick sections using a Leica VT1200S vibratome; dorsal hippocampus regions from ten brain hemisphere sections per mouse were transferred to histology slides and neuronal DiOListic labelling was performed as previously described (38–41). Briefly, 1,1′-Dioctadecyl-3,3,3′,3′-Tetramethylindocarbocyanine Perchlorate (DiI; Life Technologies)-coated 1 µm tungsten particles were fired into sections through an inverted cell culture insert (8.0 µm; BD Falcon, BD Biosciences) at a pressure of 80–100 psi (Gene Gun system; BioRad). After incubation at RT for 1 h to permit dye diffusion, sections were fixed in 4 % PFA and mounted in FluorSave (Millipore).

Confocal images of sections were captured using the Leica SP8 Lightning confocal microscope (63x objective; z-axis interval 0.2 µm) and the images deconvoluted (Leica Lightning Deconvolution). Secondary apical dendrites from dye-labeled neurons in the CA1 hippocampal area were imaged to examine dendritic spine protrusions. To reduce operator bias, all images were blinded and processed as a single batch. Images were subjected to automated analysis using the Imaris FilamentTracer module (version 9.2, Bitplane, Zurich, Switzerland). The SpineClassifier MATLAB extension was used to classify the spine subtypes (stubby, mushroom, and thin) according to their morphologies.

2.10. Open-field and novel object recognition behavioural tests

All tests were performed with mice randomised and the operator blinded to group. Animals were acclimatised to the experimental room in their home cages for a week to minimize stress and the experiments were conducted in a dimly room with red lights.

The open-field (OF) test was carried out in a box (40 x 40 x 40 cm) with opaque sides. The mouse was placed in the middle of the box at the beginning of each trial, and its movements were video recorded for 7 min. The percentage of time spent in a marked central zone was captured by viewing the videos and measuring time spent in peripheral and central zones (Gellert & Varga, 2016).

Novel object recognition (NOR) testing was performed in the same 40 x 40 x 40 cm box but with visual cues included on the walls. Mice were first habituated to the box in the absence of objects on two consecutive days (10 min/day). Next day (Day 1; training phase), two identical objects were presented for 10 min (A and A’ objects) and time exploring each object measured. On Day 2 (test phase), the same mice were exposed for 10 min to an object familiar from the training (A) and a novel object (B) and time exploring each object recorded as before. Scent cues were eliminated from the box and objects by cleaning between trials (Huang & Hseuh, 2014).

2.11. Statistical analysis

GraphPad Prism Software (version 9.4.1, San Diego, California, USA) was used for statistical analyses. For in vitro investigations, bars denote the mean and standard error of the mean, and each data point represents a separate experiment that was carried out in duplicate. For in vivo experiments, all animals survived to the planned endpoint, and all data points were thus included in analysis. Each data point corresponds to one animal, and bars show means +/- SEM. The unpaired t-test was used to determine statistical significance between two groups, and one-way ANOVA was used for multiple groups. p-values of *p < 0.05, **p < 0.01, ***p < 0.001. All histopathologic quantification and analysis, including DiOListics, were performed blinded to experimental groups. Each figure legend contains statistical information for each experiment and graph, including the statistical tests performed, the precise value of n (number of animals, samples), and dispersion and precision measurements (mean, SEM, etc.).

3. Results

3.1. C7 deficiency reduces brain complement dysregulation, amyloid load, synapse loss and cognitive impairment in AppNL−G−F mice

We have previously shown that AppNL−G−F mice have increased levels of complement activation products (C3b/iC3b/C3c and TCC) in brain homogenates compared to wild-type controls, demonstrating complement dysregulation in the brain (Carpinati et al., 2022). Here we explored the impact of C7 deficiency on complement dysregulation and its downstream effects in AppNL−G−F mice aged 8–9 months. Female AppNL−G−F/C7−/− mice had markedly reduced (to background) TCC levels in brain extracts (Fig. 1B; p = 0.0027) when compared to complement-sufficient female AppNL−G/F mice; in contrast, levels of C3b/iC3b/C3c, an upstream activation product, were not impacted by C7 deficiency (Fig. 1B; p = 0.9042). AppNL−G−F/C7−/− mice showed significantly reduced levels of IL-1β (Fig. 1C; p = 0.0237) and Aβ in TBP (tissue bound protein) (Fig. 1D; p = 0.0482) in brain extracts compared to complement-sufficient matched AppNL−G−F. We chose to measure Aβ

357
1–42 because of its pathological relevance and the robust elevation previously reported in AppNL−/−F mouse brain (Saito et al., 2014). Synapse number is reduced in AppNL−/−F mice compared to wildtypes and provides an early index of neurodegeneration in the model (Saito et al., 2014). To explore whether deficiency of C7 impacted synapse loss we measured synapse number using DiOlistics (Stafend & Meisel, 2011); brain sections from female AppNL−/−F and AppNL−/−F/C7−/− mice were imaged in identical areas in the CA1 region of the hippocampus; total spine number and numbers for the different morphological spine subtypes were automatically quantified using Imaris and ImageJ software as described in methods. Overall spine density was significantly higher in AppNL−/−F/C7−/− mice compared to AppNL−/−F controls (Fig. 1E; F; p < 0.0001). Comparison of the different morphological spine subtypes showed that this difference was greatest for thin and stubby spines (Fig. 1E; F; p < 0.0001, p = 0.0082 respectively).

Given that synapse density in the CA1 hippocampus region is associated with cognition and memory in mice and men (Morrison & Baxter, 2012, Perez-Cruz et al., 2011), we investigated whether the rescue of synapses observed in AppNL−/−F/C7−/− mice initiates MAC assembly. Performance of female AppNL−/−F and AppNL−/−F/C7−/− mice was compared in two behavioural tests, the open field (OF) and novel object recognition (NOR) tests. The OF test is a common measure of exploratory behaviour, while NOR tests object recognition memory. In the OF test, AppNL−/−F/C7−/− mice showed greater exploration, spending significantly more time in the centre of the test field compared to AppNL−/−F controls which moved less and favoured the field edges (Fig. 1G; p = 0.0421). In the NOR test the AppNL−/−F/C7−/− mice spent significantly more time exploring the novel object compared to AppNL−/−F (Fig. 1H, p < 0.0001).

3.2. C7 add-back in AppNL−/−F/C7−/− mice initiates MAC assembly, increases brain IL-1β and Aβ levels, exacerbates synapse loss and cognitive impairment

To confirm that the observed protective effect of C7 deficiency on
disease and cognition in the App\textsuperscript{NL-G-F} mouse was caused by absence of MAC, male App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} mice were given human C7 protein over a week in amounts that matched C7 levels in wildtype mice and fully restored serum haemolytic activity (Fig. 2A). Mice were subjected to behavioural testing on day 7 then sacrificed. Human C7 was detected in brain homogenates from all C7-treated App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} mice but not in untreated App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} mice (Fig. 2B). Levels of C3 fragments in brain homogenates were not impacted by administration of C7 (Fig. 2C; p = 0.7250); in contrast, levels of TCC, a readout for MAC formation, were significantly increased in C7-treated App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} mice (Fig. 2D; p = 0.0130). Levels in brain homogenates of the inflammatory cytokine IL-1\textbeta (Fig. 2E; p = 0.0492) and the APP-derived Aβ peptide (Fig. 2F, p = 0.0015) were significantly increased in App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} mice following add-back of C7. Measurement of dendritic spines in CA1 hippocampus showed that administration of C7 for just one week in App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} male mice caused a significant reduction in spine density compared to App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} controls (Fig. 2G, H, p = 0.0028), with the thin spines being mainly impacted (Fig. 2H p = 0.0037). In the OF and NOR tests of cognition and memory, App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} male given human C7 performed significantly less well compared to control App\textsuperscript{NL-G-F}/C7\textsuperscript{-/-} male in both tests (Fig. 2I, J; p < 0.0001, p = 0.0010 respectively).

For all analyses, an unpaired two-tailed t-test was used to compare the two groups. Each point represents one animal. Error bars correspond to SEM and p values are included. ns = not significant.

3.3. Systemic treatment with anti-C7 blocking mAb reduces MAC assembly, brain IL-1β and Aβ levels, synapse loss and cognitive impairment in App\textsuperscript{NL-G-F} mouse

To investigate whether a tool anti-complement agent could inhibit complement dysregulation and MAC formation in the App\textsuperscript{NL-G-F} mouse, we utilised our recently developed anti-C7 blocking mAb (73D.1; Zelek & Morgan, 2020). The mice were administered 73D1 anti-C7 mAb systemically over a month using a dosing schedule known to completely abrogate serum complement lytic activity in haemolysis assays. As expected, CP haemolytic activity in serum was suppressed in the 73D1-treated animals throughout the experiment whereas isotype control (D1.3) mAb had no effect (Fig. 3A, p < 0.0001). Mice were subjected to behavioural testing and then sacrificed on day 28. Levels of C3 fragments in brain homogenates were not impacted by administration of the anti-C7 mAb (Fig. 3B, p = 0.935); in contrast, levels of TCC, a readout for MAC formation, were more than halved in anti-C7-treated mice (Fig. 3C, p = 0.0152). Levels in brain homogenates of the inflammatory cytokine IL-1β were reduced, albeit not significantly, in anti-C7-treated mice (Fig. 3D), while levels of Aβ peptide were significantly reduced in TBP (tissue bound protein) (Fig. 3E, p = 0.0372). Measurement of dendritic spines in CA1 hippocampus showed that systemic administration of anti-C7 blocking mAb for a month in App\textsuperscript{NL-G-F} female mice caused a significant increase in spine density compared to isotype control-treated App\textsuperscript{NL-G-F} female mice (Fig. 3F), with rescue of thin spines predominating (Fig. 3G, p = 0.0156). In the OF and NOR tests, App\textsuperscript{NL-G-F} female mice treated for 28 days with the anti-C7 mAb performed significantly better than isotype control-treated mice in both tasks (Fig. 3H, I, p < 0.0001, p = 0.0077 respectively).

4. Discussion

AD is the most prevalent type of dementia and is without an effective cure. The lack of a comprehensive understanding of the underlying pathological mechanisms is a significant obstacle to the development of AD therapies. Most current AD drugs, including the acetylcholine esterase inhibitors (galantamine, rivastigmine, tacrine, and donepezil) and N-methyl-D-aspartate receptor blockers (memantine), target symptoms not the underlying pathology (Pardo-Moreno et al., 2022; Gupta et al., 2021; Imbimbo & Watling, 2021; Karran & De Strooper, 2022; Valiukas et al., 2022). The recent crop of anti-Aβ monoclonal antibodies entering the clinic (adunumab, lecanemab), while targeting and effectively clearing the hallmark amyloid plaque pathological markers, have a modest effect on disease progression and numerous toxicities (Haddad et al., 2022; Kuller & Lopez, 2021; Andrews et al., 2019; Salloway et al., 2019). It is now clear that neuroinflammation is a significant factor in the development of neurodegeneration and an abundance of evidence that anti-inflammatory drugs might impact progression in AD (Lambert et al., 2013; Lambert et al., 2009; De Cordoba et al., 2012; Morgan et al., 2017; Cervellati et al., 2018; Franceschi et al., 2014; Tenner, 2020; Carpanini et al., 2019, Spanenberg & Green, 2017; Hoogland et al., 2017).
An understanding of the factors driving neuroinflammation in AD and other dementias would enable informed selection and better targeting of inflammation-blocking therapies. Complement, a potent driver of inflammation in many diseases, is strongly implicated in AD based on evidence from genetics, biomarkers and models (Lambert et al., 2013; Lambert et al., 2009; De Cordoba et al., 2012; Morgan et al., 2017; Veteleanu et al., 2023). Complement activation in the brain causes inflammation, activates and directs microglia and directly damages synapses, neurons and other brain cells (Bohison & Tenner, 2023; Hong et al., 2016; Carpanini et al., 2022; Tenner, 2020; Daskoulidou et al., 2023; Schartz & Tenner, 2020). Of the several pro-inflammatory complement effectors, the MAC is uniquely relevant because it not only directly damages vulnerable targets but also activates diverse target cells to enhance inflammation (Morgan, 2016; Triantafilou et al., 2013; Zelek & Morgan, 2022; Carpanini et al., 2022). In brain, MAC damages synapses directly by "microlysis" and indirectly by triggering inflammatory pathways which in turn activate microglia.

We previously showed that C6 deficiency in the 3xTg AD model reduced synapse loss, implicating MAC in the process (Carpanini et al., 2022). This observation, together with the evidence that complement dysregulation in AD models involves activation of the terminal pathway with the generation of MAC, led us to investigate the pathological role of MAC in the App\textsuperscript{NL-\textit{G}\textsuperscript{F}} AD mouse model and test the feasibility of targeting MAC for treatment of AD. We performed three experiments: first, we backcrossed App\textsuperscript{NL-\textit{G}\textsuperscript{F}} mice to C7 deficiency (App\textsuperscript{NL-\textit{G}\textsuperscript{F}/C7}\textsuperscript{-/-}); second, we added back human C7 to these App\textsuperscript{NL-\textit{G}\textsuperscript{F}/C7}\textsuperscript{-/-} mice; third, we treated the App\textsuperscript{NL-\textit{G}\textsuperscript{F}} mice with a systemic anti-C7 mAb. In each
experiment, we examined the impact of the intervention on complement dysregulation in the brain, neuropathological parameters and cognitive state. For complement dysregulation we measured C3 activation products as an index of activation pathway dysregulation and TCC as an index of terminal pathway dysregulation and MAC formation. Brain levels of the APP-derived peptide Aβ were measured as an index of amyloid load, synapse density as a read-out for neurodegeneration and levels of the pro-inflammatory cytokine IL1-β as a marker of inflammasome-triggered inflammation, relevant to this study because we and others have shown that MAC is a potent activator of the inflammasome in diverse cell types (Morgan, 2016; Triantafillou et al., 2013). From the toolbox of behavioural tests in mice we selected Open Field (OF), a test of general locomotor ability and anxiety, and Novel Object Recognition (NOR), testing aspects of learning and memory (Gellert & Varga, 2016; Huang & Hsu, 2014). These tests were selected for ease of use and to cover a broad range of behaviours. In preliminary studies we showed that C7 deficiency in wild-type mice at 2–3 months had no impact on synapse density.

Brain extracts from AppNL-G-F mice at 8–9 months contained substantial amounts of C3 fragments and TCC, demonstrating profound complement dysregulation involving the activation and terminal pathways. In the AppNL-G-F/C7+/− mice, C3 fragment levels in brain extracts were elevated to the same degree as AppNL-G-F, in contrast, TCC levels were at assay background, demonstrating that absence of C7 had blocked terminal pathway activation and MAC formation. Absence of MAC was associated with decreased amyloid load in brain as assessed by measuring the APP-derived peptide Aβ, and with reduced levels of the inflammatory cytokine IL1-β, reflecting elimination of MAC-triggered inflammasome activation in brain cells (Triantafillou et al., 2013). Although we do not address the source of IL-1β in this study, microglia are known to express inflammasome components and are the primary source of IL-1β in the inflamed brain (Yao et al., 2023). Remarkably, AppNL-G-F/C7+/− mice had significantly reduced levels of Aβ peptides in brain extracts, indicating a decreased amyloid load compared to AppNL-G-F controls. We are currently investigating whether the reduction in neuroinflammation associated with absence of MAC is responsible for reduced amyloid load. Compared to AppNL-G-F controls, AppNL-G-F/C7+/− mice had significantly greater numbers of synaptic spines measured in CA1 hippocampus; indeed, numbers were similar to those measured in wildtype mice of the same age (Bevan et al., 2020).

These data are congruent with our previous demonstration that C6 deficiency caused reduced synapse loss in 3xTg mice and further support our suggestion that MAC directly damages synapses (Bevan et al., 2020; Carpanini et al., 2022). Hippocampal synapse loss is strongly associated with cognitive impairment in man and models (Morrison & Baxter, 2012, Perez-Cruz et al., 2011; Frankfurt and Luine, 2015; Subramanian et al., 2020), and AppNL-G-F mice have age-dependent cognitive deficits from ~ 6 months of age (Whyte et al., 2017; Mehta et al. (2018)). We showed that AppNL-G-F/C7+/− mice tested at 8–9 months performed significantly better than matched AppNL-G-F controls in open field and novel object recognition tests, confirming a rescue of cognitive function.

To further confirm the role of MAC, we then administered human C7 to the AppNL-G-F/C7+/− mice for a week to restore capacity to generate MAC. Human and mouse terminal pathway proteins are compatible between species, as confirmed here by the restoration of serum haemolytic activity. The add-back of human C7 was restricted to just one week because the immune response to the human protein generates neutropenia in ALB transgenic mice (Hsiao et al., 2002). Functional restoration was confirmed systemically by demonstrating full haemolytic activity in serum and centrally by showing a marked increase (from baseline) of TCC levels in brain and human C7 protein detected in brain. Entry of C7 (Mr ~ 105 kDa) into the brain confirms previous reports of blood brain barrier (BBB) impairment in the AppNL-G-F mouse (Xie et al., 2021). Restoration of capacity to generate MAC for just one week acutely increased IL-1β and Aβ peptide levels in brain homogenates, causing a significant decrease of neuronal synaptic density and reduced performance in the OF and NOR cognitive tests compared to vehicle-treated AppNL-G-F/C7+/− mice. The effects of C7 restoration for just one week are remarkable, demonstrating an acute effect of MAC, likely by inducing acute inflammation via NLRP3 activation and direct destruction of synapses. In support of this, others have shown that inflammation, and specifically IL-1β, can trigger degeneration of neurons and formation of Aβ aggregates (Bai and Zhang (2021)).

The rapid impact of restoring MAC reflects the fact that early stages of complement dysregulation continue in the AppNL-G-F/C7+/− brain, priming for rapid terminal pathway activation on restoring C7. These findings also imply that absence of MAC and associated inflammation, rather than reduced accumulation of Aβ, are responsible for the impact on neurodegeneration and behaviour.

Given that the absence of MAC is protective, and its presence exacerbates AD pathology in the AppNL-G-F mouse, we investigated the therapeutic possibility of systemic blockade of MAC formation in vivo. We have previously reported that two weeks systemic treatment of 6 month old AppNL-G-F mice with the anti-C7 mAb 73D1 did not have an effect on overall synapse number in CA1 hippocampus; however, we did find a significant increase in synapses in peri-plaque regions (Carpanini et al., 2022). Others have shown that therapeutic anti-amyloid mAb delivered systemically in AppNL-G-F mice at either 3–5 months or 7–9 months accesses the brain, albeit markedly better in the older mice (Gustavsson et al., 2023). These findings provoked us to repeat the study in older AppNL-G-F mice (9 months) in which the BBB is likely more impaired (Xie et al. (2021)), treated systemically for four weeks with the anti-C7 mAb. Compared to isotype control-treated AppNL-G-F systemic administration of mAb 73D1 for 4 weeks at a dose that completely blocked systemic complement lytic activity, caused a significant reduction in levels of TCC in brain homogenates, confirming target engagement. Brain IL1-β levels were markedly reduced in anti-C7-treated AppNL-G-F mice, as were Aβ levels in brain protein extracts. Anti-C7 treatment significantly increased overall hippocampal synaptic spine density and improved performance in the OF and NOR cognitive tests compared to isotype control treated AppNL-G-F mice, demonstrating a marked impact of the anti-C7 mAb on biomarkers, pathology and behaviour. There is an abundance of literature linking spine density to behaviour and cognition in different AD (and other NDD) models in rodents (Frankfurt & Luine, 2015; Subramanian et al., 2020). Neuronal network features can be affected by subtle changes in dendritic spine densities or size, which may result in altered moods or cognitive functions, problems with learning and memory, and hypersensitivity to pain. (Gipson & Olive, 2017).

In our experiments the spines that were predominantly affected were thin spines, thought to be particularly plastic and linked to learning. Also demonstrated by the cognitive improvements that are related to the higher number of thin spines.

5. Conclusions

Others have reported that C3 deficiency in the APP/PS1 mouse AD model was associated with significantly better performance on learning and memory tasks (Shi et al., 2017); here we confirm that complement deficiency preserves cognition in an AD model and identify the MAC as a critical factor. Our data show that complement dysregulation and MAC formation are important drivers of pathology in the AppNL-G-F mouse AD model and suggest that MAC is a valid therapeutic target for AD. They confirm that the BBB is sufficiently impaired in 9 month old AppNL-G-F mice to allow entry of systemically administered anti-C7 mAb into the brain, enough to block all available C7, stop MAC formation, reduce brain inflammation and amyloid deposition, reduce synapse loss and improve cognition. Because this approach relies on BBB impairment associated with advanced pathology, it is likely that treatment with unmodified anti-C7 mAb earlier in the disease process would be ineffective because the mAb would be excluded. To counter this and enable treatment of early disease, much more relevant to human AD, our current focus is on development of BBB-penetrant C7-blocking mAb or
other moieties.

Author contributions

RJB and WMZ performed the laboratory analysis. BPM and WMZ designed the experiments. WMZ wrote the first draft of the manuscript. All authors read and approved the final version of the manuscript.

CRediT authorship contribution statement

Violeta M. Zelek: Ryan J. Bevan: Visualization, Methodology, Formal analysis, Data curation. Bryan Paul Morgan: Writing – review & editing, Visualization, Validation, Supervision, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

Data will be made available on request.

Acknowledgments

This work is supported by the UK Dementia Research Institute which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer’s Society and Alzheimer’s Research UK. WMZ is supported by Race Against Dementia Alzheimer’s Research Council, Alzheimer Society and Alzheimer’s Research UK Fellowship Award.

References


